别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析

doi:10.19803/j.1672-8629.20230806

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 1068-1070.
DOI: 10.19803/j.1672-8629.20230806

别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析

严妍¹, 刘乃一², 乔玲³, 张毅¹, 杨晨^4,*

¹天津市环湖医院药剂科,天津 300350;
²天津市天津医院药剂科,天津 300211;
³邢台医学高等专科学校第一附属医院药剂科,河北邢台 054001;
⁴天津医科大学总医院药剂科,天津 300052

收稿日期:2023-12-29 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*杨晨,男,硕士,副主任药师,临床药学。E-mail: ycnpharma@gmail.com
作者简介:严妍,女,硕士,主管药师,临床药学。

One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome

YAN Yan¹, LIU Naiyi², QIAO Ling³, ZHANG Yi¹, YANG Chen^4,*

¹Department of Pharmacy, Tianjin Huanhu Hospital, Tianjin 300350, China;
²Department of Pharmacy, Tianjin City Tianjin Hospital, Tianjin 300211, China;
³Department of Pharmacy, the First Hospital of Xingtai, Xingtai Hebei 054001, China;
⁴Department of Pharmacy, General Hospital of Tianjin Medical University, Tianjin 300052, China

Received:2023-12-29 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的探讨暴发性1型糖尿病与别嘌醇诱发的药物超敏反应综合征的相关性,为临床提供参考。方法研究1例携带HLA*B5801的患者使用别嘌醇后出现超敏反应并继发暴发性1型糖尿病的病例,结合相关文献,分析了其病例特点及药物导致不良反应的相关机制,并梳理了对此类患者的治疗措施。结果患者胰岛功能完全丧失,今后需长期使用多次胰岛素注射方案控制血糖。既往研究和病例报告提示该不良反应与别嘌醇的使用可能相关。结论此案例提示使用别嘌醇前应进行HLA-B*5801基因检测。临床医师应注意药物超敏反应综合征有继发自身免疫性疾病的风险。

关键词: 暴发性1型糖尿病, 别嘌醇, 不良反应, 药物诱导超敏反应综合征, HLA-B*5801, 药物性皮疹, 药学监护

Abstract: Objective To explore the correlation between fulminate type 1 diabetes mellitus and allopurinol-induced drug hypersensitivity syndrome, and to provide reference for clinical practice. Methods A patient with HLA-B*5801 allele who developed secondary fulminant type 1 diabetes mellitus after allopurinol-induced hypersensitivity syndrome and was reported. The characteristics of the case and the related mechanism of drug-induced adverse reactions were analyzed according to the relevant literature, and the treatment measures for such patients were sorted out. Results The patient lost islet function completely and needed long-term multiple daily insulin injection to control blood glucose in the future. Previous studies and case reports suggest that this adverse event may be related to the use of allopurinol. Conclusion This case suggests that HLA-B*5801 gene testing should be performed before allopurinol treatment. Clinicians should be aware of the risk of secondary autoimmune diseases associated with drug-induced hypersensitivity syndrome.

Key words: fulminant type 1 diabetes mellitus, allopurinol, adverse reaction, drug-induced hypersensitivity syndrome, HLA-B*5801, drug-indused skin rash, pharmaceutical care

中图分类号:

严妍, 刘乃一, 乔玲, 张毅, 杨晨. 别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析[J]. 中国药物警戒, 2024, 21(9): 1068-1070.

YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen. One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20230806

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/1068

参考文献

[1] Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2020, 36(1): 1-13.
[2] FITZGERALD JD, DALBETH N, MIKULS T, et al.2020 American college of rheumatology guideline for the management of gout[J]. Arthritis Care Res (Hoboken), 2020, 72(6): 744-760.
[3] YASEEN W, AUGUSTE B, ZIPURSKY J.Allopurinol hypersensitivity syndrome[J]. CMAJ, 2023, 195(13): E483.
[4] CABAÑAS R, RAMÍREZ E, SENDAGORTA E, et al. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome[J]. J Investig Allergol Clin Immunol, 2020, 30(4): 229-253.
[5] QIU JL, ZHAN SP, HUANG H, et al.One case report and literaturereview of fulminant type 1 diabetes mellitus caused by drug-induced hypersensitivity syndrome[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2017, 25(5): 464-467.
[6] IMAGAWA A, TACHIBANA M.Fulminant type 1 diabetes: recent research progress and future prospects[J]. Diabetol Int, 2020, 11(4): 336-341.
[7] ZHANG XZ, YUAN FY, XU D, et al.Fulminant type 1 diabetes mellitus and graves disease caused by drug-induced hypersensitivity syndrome followed by pure red cell aplasia with thymoma: report and literature review[J]. Journal of Rare and Uncommon Diseases(罕少疾病杂志), 2022, 29(7): 8-11.
[8] ONUMA H, TOHYAMA M, IMAGAWA A, et al.High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome[J]. J Clin Endocrinol Metab, 2012, 97(12): E2277-E2281.
[9] SOMMERS LM, SCHOENE RB.Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new-onset diabetes mellitus[J]. Arch Intern Med, 2002, 162(10): 1190-1192.
[10] STIRTON H, SHEAR NH, DODIUK-GAD RP.Drug reaction with eosinophilia and systemic symptoms (DReSS)/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS[J]. Biomedicines, 2022, 10(5): 999.
[11] HAMA N, ABE R, GIBSON A, et al.Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis[J]. J Allergy Clin Immunol Pract, 2022, 10(5): 1155-1167.
[12] QIU J, YIN W, WANG R, et al.Fulminant type 1 diabetes: focusing on triggering factors[J]. Diabetes Metab Res Rev, 2024,40(2): e3731.
[13] KANO Y, TOHYAMA M, AIHARA M, et al.Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian research committee on severe cutaneous adverse reactions (ASCAR)[J]. J Dermatol, 2015, 42(3): 276-282.
[14] ZHU B, WU J, CHEN G, et al.Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature[J]. Front Endocrinol (Lausanne), 2019, 16(10): 474.
[15] KAWASAKI E.Anti-islet autoantibodies in type 1 diabetes[J]. Int J Mol Sci, 2023, 24(12): 10012.
[16] HOSOKAWA Y, HANAFUSA T, IMAGAWA A.Pathogenesis of fulminant type 1 diabetes: genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research[J]. J Diabetes Investig, 2019, 10(5): 1158-1164.
[17] Chinese Diabetes Society, Chinese Endocrinologist Association, Chinese Society of Endocrinology, Chinese Pediatric Society, Chinese Society of Endocrinology, Chinese Medical Association, et al. Guidelines for the diagnosis and treatment of type 1 diabetes mellitus in China (2021 edition)[J]. Chinese Journal of Diabetes Mellitus(中华糖尿病杂志), 2022, 14(11): 1143-1250.
[18] SAYAMA K, IMAGAWA A, OKITA K, et al.Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment[J]. Diabetologia, 2005, 48(8): 1560-1564.

别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析

One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	路振凯, 杨顶权, 谢振年, 王连心, 黎元元, 王志飞, 崔鑫, 谢雁鸣. 《外用中成药临床应用药物警戒指南》解读与启示[J]. 中国药物警戒, 2024, 21(9): 1029-1033.
[2]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[3]	林璐, 詹陆川, 刘晓琦, 刘菊娥, 王来友, 曾颖, 赖伟华. 基于中国医院药物警戒系统建立地高辛不良事件主动监测电子触发器[J]. 中国药物警戒, 2024, 21(9): 1039-1043.
[4]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[5]	张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.
[6]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[7]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[8]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[9]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[10]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[11]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[12]	李芳, 龙秀英, 柏娜, 魏京霞. 阿托伐他汀钙片致全身严重皮疹1例分析[J]. 中国药物警戒, 2024, 21(8): 939-942.
[13]	晁滢, 张学梅, 张成健, 王贝. 注射用头孢曲松钠致儿童输尿管结石及胆囊结石1例分析[J]. 中国药物警戒, 2024, 21(8): 943-945.
[14]	郭海嬿, 何波, 闫鸿丽, 杨雪婷. 稳心颗粒致持续性呃逆1例分析[J]. 中国药物警戒, 2024, 21(8): 946-948.
[15]	王丹, 董铎, 田春华. 我国药物警戒制度发展历程和思考[J]. 中国药物警戒, 2024, 21(7): 735-740.